300653 Yantai Zhenghai Bio-Tech
- 20.78
- +0.08+0.39%
Yantai Zhenghai Bio-Tech News
The Three-year Underlying Earnings Growth at Yantai Zhenghai Biotechnology (SZSE:300653) Is Promising, but the Shareholders Are Still in the Red Over That Time
If you love investing in stocks you're bound to buy some losers. But long term Yantai Zhenghai Biotechnology Co., Ltd. (SZSE:300653) shareholders have had a particularly rough ride in the last three
Yantai Zhenghai Bio-Tech (300653.SZ): During the use of active biological bone, doctors decide on the selection of internal fixation devices based on clinical needs. Currently, no related supporting medical devices are provided.
Zhenghai Bio-tech (300653.SZ) stated on the investor interaction platform that the company's active biological bone product is mainly used to fill bone defects caused by trauma or surgery that do not affect the stability of bone structure. During the use of active biological bone, doctors determine the choice of internal fixation devices according to clinical needs, and the company currently does not provide relevant supporting medical devices. Umbilical cord mesenchymal stem cells are currently in the product process validation stage. The company will continue to cultivate in the field of regenerative medicine, actively researching and developing products and technologies including signal molecules, seed cells, additive manufacturing, genetic engineering, and synthetic biology to create medical devices and treatments.
Yantai Zhenghai Bio-Tech (300653.SZ) equity distribution in 2023: 8.01804 yuan per 10 shares.
Zhenghai Bio-Tech (300653.SZ) announced its annual equity distribution plan for 2023: based on the company's existing total share capital after deducting the repurchased shares, it will distribute RMB 8.01804 in cash per 10 shares to all shareholders. The equity distribution share registration date is June 13, 2024, and the ex-rights and ex-dividend date is June 14, 2024.
Yantai Zhenghai Bio-tech (300653.SZ) has repurchased 0.1679% of its shares, at a cumulative cost of 7.1857 million yuan.
On June 5th, Gelunhui reported that Yantai Zhenghai Bio-Tech (300653.SZ) announced that as of May 31, 2024, the company repurchased 302,300 shares of the company's stock through a share repurchase special securities account through centralized bidding trading, accounting for 0.1679% of the company's total share capital, with a highest transaction price of 24.83 yuan/share, a lowest transaction price of 22.90 yuan/share, and a total amount paid of 7,185,656.74 yuan (excluding transaction fees). This buyback complies with the company's share repurchase plan and relevant laws and regulations.
Zhenghai Biology (300653.SZ): The company's active biological bone products were officially marketed in early 2024
Gelonghui, May 15, 丨 Zhenghai Biotech (300653.SZ) was surveyed by specific subjects and said that the company's active biological bone products were officially marketed in early 2024. In the first quarter, it mainly completed online connections in more than 2/3 provinces across the country and admissions work in some hospitals. In the second quarter, it will continue to steadily expand the scope of admission, and sales of related products will gradually increase.
Yantai Zhenghai Biotechnology Co., Ltd. (SZSE:300653) Adds CN¥742m in Market Cap and Insiders Have a 42% Stake in That Gain
Key Insights Yantai Zhenghai Biotechnology's significant insider ownership suggests inherent interests in company's expansion The top 7 shareholders own 50% of the company Institutions own 15% of
Zhenghai Biotech (300653.SZ): Initial repurchase of 17,500 shares involving 4181,000 yuan
Gelonghui, April 3, 丨 Zhenghai Biotech (300653.SZ) announced that on April 3, 2024, the company used its own funds to repurchase shares through centralized bidding transactions for the first time through a special stock repurchase securities account. The number of shares repurchased was 17,500 shares, accounting for 0.01% of the company's current total share capital. The highest transaction price of the repurchase was 23.98 yuan/share, and the minimum transaction price was 23.82 yuan/share. The total transaction amount was 4181.37 million yuan (excluding transaction fees).
Zhenghai Biology (300653.SZ): The main products in the dental department are oral repair membranes and bone repair materials. Currently, the two products are not involved in collection
Gelonghui April 2 丨 Zhenghai Biotech (300653.SZ) was surveyed by specific subjects on April 1, 2024, on “Will oral membrane powder products be collected?” The company replied that the company's main products in the dental department are oral repair membranes and bone repair materials. Currently, the two products are not involved in collection. Product collection is affected by many factors, and the company will pay close attention to the promotion and implementation of relevant collection policies.
Zhenghai Biotech (300653.SZ): Active biological bone products have completed the conversion verification process within 2023 and officially launched for sale
Gelonghui April 2 丨 Zhenghai Biotech (300653.SZ) was surveyed by specific subjects on April 1, 2024, on “Sales progress of active biological bone products?” The company replied that according to the “National Organization's Centralized Volume Procurement Notice for Artificial Crystals and Sports Medicine Medical Consumables (No. 2)” issued by the Tianjin Pharmaceutical Procurement Center in September 2023, the company's product active biological bone is not within the scope of this collection. The company's active biological bone products have completed the conversion verification process within 2023 and are officially marketed. Up to now, the Internet connection work has been completed in more than 2/3 provinces, related markets
Zhenghai Biotech (300653.SZ): Net profit for 2023 increased by 2.98% to 191 million yuan, plans to pay 10 to 8 yuan
On April 1, Ge Longhui Biotech (300653.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 414 million yuan, a year-on-year decrease of 4.52%; net profit attributable to shareholders of listed companies was 191 million yuan, up 2.98% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 168 million yuan, down 2.71% year on year; basic income per share was 1.06 yuan; it plans to distribute a cash dividend of 8.00 yuan (tax included) for every 10 shares to all shareholders.
Zhenghai Bio-Tech Gets Nod for Oral Restorative Film
Yantai Zhenghai Bio-Tech (SHE:300653) obtained the approval of China's National Medical Products Administration to register its oral restorative film, according to the company's filing on the Shenzhen
Zhenghai Biology (300653.SZ): Active Biological Bone currently has sufficient production capacity and sales promotion work is being carried out according to the plan
On March 6, Gelonghui Biotech (300653.SZ) said on the investor interactive platform that active biological bone currently has sufficient production capacity, sales promotion work is being carried out according to plan, and the company will make every effort to promote the marketing and sales of active biological bone.
Little Excitement Around Yantai Zhenghai Biotechnology Co., Ltd.'s (SZSE:300653) Earnings As Shares Take 29% Pounding
Yantai Zhenghai Biotechnology Co., Ltd. (SZSE:300653) shareholders that were waiting for something to happen have been dealt a blow with a 29% share price drop in the last month. For any long-term
Zhenghai Biotech (300653.SZ): Verification of active biological bone conversion was completed last year and mass production work was carried out in the new plant
On January 26, Gelonghui Biotech (300653.SZ) said on the investor interactive platform that the verification of active biological bone conversion was completed last year, mass production work was carried out in the new factory area, and the listing and sales work is currently being carried out normally.
Zhenghai Biology (300653.SZ): Online admission of active biological bones continues to advance
On January 9, Gelonghui Biotech (300653.SZ) said on the investor interactive platform that the online admission process for active biological bones is continuing, and more than 2/3 of the provinces have now completed the online registration process.
Earnings Are Growing at Yantai Zhenghai Biotechnology (SZSE:300653) but Shareholders Still Don't Like Its Prospects
The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance. That
Zhenghai Biology (300653.SZ): Sales of active biological bone have been carried out normally
On January 5, Gelonghui Biotech (300653.SZ) said on the investor interactive platform that sales of active biological bone have been carried out normally. Please pay attention to the company's regular reports on product sales.
Zhenghai Biotech (300653.SZ): No share repurchase has been implemented
Gelonghui January 3 丨 Zhenghai Biotech (300653.SZ) announced that as of December 31, 2023, the company had not implemented a share repurchase.
Zhenghai Biology (300653.SZ): Active biological bone conversion verification work has now been completed according to plan
Glonghui, December 22|Some investors asked Zhenghai Biotech (300653.SZ) on the investor interactive platform, “Can the conversion of active biotech stocks be completed before the 31st of this month?” The company replied that the active biobone conversion verification work has now been completed according to plan.
Zhenghai Biotech (300653.SZ): Plans to repurchase 25 million yuan to 50 million yuan of company shares
On December 20, Gelonghui Biotech (300653.SZ) announced that the total amount of capital it intends to repurchase is not less than RMB 25 million, and not more than RMB 50 million of the company's shares. The repurchase price will not exceed RMB 44.90 per share.
Analysis
Price Target
No Data
